Fractyl Health receives Nasdaq delisting notice over $1.00 minimum bid price
Fractyl Health said Nasdaq notified it on September 10, 2026 that its stock is subject to delisting because it did not regain compliance with the $1.00 minimum bid price requirement by September 9, 2026. The company intends to request a hearing before a Nasdaq Hearings Panel, which would keep its stock listed while the process runs, and has proposed a reverse stock split of 1-for-5 to 1-for-15 for stockholder approval.
Key points
- Nasdaq letter dated September 10, 2026 says the stock is subject to delisting unless the company timely requests a hearing
- Company did not meet the $1.00 minimum bid price within the 180-calendar day grace period ending September 9, 2026
- Company intends to request a Panel hearing, which automatically stays suspension or delisting
- Proxy statement filed August 24, 2026 seeks approval for a reverse split ranging from 1-for-5 to 1-for-15
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.